Treating Afib with antithrombotics: updated CHEST guideline

  • Chest

  • curated by Jenny Blair, MD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Among patients with Afib and at least 1 CHA2DS2VASc stroke risk factor besides female sex, oral anticoagulants (OAC) are preferred.

Why this matters

  • New options and research relating to Afib thromboprophylaxis have emerged since the 2012 (9th) edition.
  • Most patients with Afib die from cardiac causes rather than stroke, suggesting a need for holistic prevention approaches.

Description

  • 60 recommendations by CHEST expert panel relating to stroke prophylaxis among subgroups of Afib patients.
  • Only 6 carried over from previous guideline.
  • Recommendations based on systematic review and meta-analyses.
  • Funding: American College of Chest Physicians.

Key details

  • Afib patients without valvular disease, with low stroke risk per CHA2DS2VASc: no antithrombotic therapy (strong recommendation [SR], moderate-quality evidence [MQE]).
  • Afib patients with ≥1 (men) or ≥2 (women) non-sex-related CHA2DS2VASc stroke risk factor(s): OAC preferred vs no therapy, aspirin, or aspirin/clopidogrel (SR/MQE).
  • Novel OAC preferred over vitamin K antagonist (VKA) (SR/MQE).
  • For all Afib patients:
    • Presence or absence of symptoms should not dictate need for anticoagulation based on stroke risk (ungraded consensus-based [UCB]);
    • Regardless of stroke risk, avoid using only aspirin or aspirin/clopidogrel for stroke prevention (SR/MQE).
  • For all Afib patients, at each visit:
    • Assess modifiable risk factors (SR/low-quality evidence);
    • If HAS-BLED score ≥3, follow-up frequently (SR/MQE).
  • For Afib patients with acute coronary syndrome or undergoing percutaneous intervention (PCI)/stenting, assess stroke risk with CHA2DS2VASc score (SR/MQE).
  • For Afib patients experiencing acute ischemic stroke:
    • Avoid heparinoids or VKA in first 48 hours (UCB);
    • Use long-term OAC for secondary prevention (SR/high quality evidence);
    • Consider beginning within 2 weeks (UCB).
  • For Afib patients who have refused OAC, revisit decision, educate (UCB).
  • Additional recommendations address cardioversion, elective PCI/stenting, dosing, proton-pump or P2Y12 inhibitors, choice of anticoagulants for survivors of stroke or gastrointestinal bleeding, left atrial appendage occlusion, carotid revascularization, pregnancy, lactation, chronic kidney disease, and cardiac surgery.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit